GlassScriptPhysician profile
Shawn Michael Whitfield
NPI 1861830200
$2,189.54
in general payments reported to CMS, 2019-2025
35 companies · $877 in 2025
The $877 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.44 · 2022: $47.30 · 2023: $26.52 · 2024: $1,213 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,116.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $500.06 | 2022-2025 | |
| Sk Life Science, INC. | $211.41 | 2024 | Xcopri |
| Pfizer INC. | $149.20 | 2024-2025 | |
| Ucb, INC. | $145.01 | 2024-2025 | Briviact, Nayzilam, Fintepla |
| Biogen, INC. | $125.38 | 2024-2025 | Vumerity |
| Emd Serono, INC. | $90.42 | 2024-2025 | |
| Lilly USA, LLC | $75.87 | 2024-2025 | Amyvid, Kisunla, Zepbound |
| Alexion Pharmaceuticals, INC. | $75.53 | 2024-2025 | Ultomiris |
| Tg Therapeutics, INC. | $71.15 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $68.65 | 2025 | |
| Argenx US, INC. | $63.70 | 2024-2025 | Vyvgart Hytrulo |
| Jazz Pharmaceuticals INC. | $57.34 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $53.44 | 2024-2025 | Nuplazid |
| Alnylam Pharmaceuticals INC. | $51.51 | 2024-2025 | Onpattro |
| Neurelis, INC. | $50.09 | 2024-2025 | Valtoco |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $35.58 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.75 | 2024 | Hyqvia |
| Medtronic, INC. | $27.42 | 2025 | Intellis Adaptivestim |
| Xeris Pharmaceuticals, INC. | $22.91 | 2024 | Recorlev |
| Inspire Medical Systems, INC. | $22.85 | 2025 | Inspire |
| Merz Pharmaceuticals, LLC | $22.27 | 2024 | Xeomin |
| Insulet Corporation | $21.66 | 2024 | Omnipod |
| Kyowa Kirin, INC. | $20.59 | 2024 | Nourianz |
| Octapharma USA, INC. | $19.81 | 2024 | Panzyga |
| Axsome Therapeutics, INC. | $18.35 | 2024 | Sunosi |
| Aucta Pharmaceuticals, INC. | $17.82 | 2025 | Motpoly Xr |
| Verity Pharmaceuticals INC. | $17.82 | 2024 | Tlando |
| Mdd US Operations, LLC | $17.81 | 2024 | Gocovri |
| Csl Behring | $17.44 | 2024 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $17.21 | 2024 | Austedo Xr |
| Lundbeck LLC | $15.69 | 2025 | Vyepti |
| Glaxosmithkline, LLC. | $14.36 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.35 | 2024 | Synjardy, Jardiance |
| Cycle Pharmaceuticals INC | $13.01 | 2024 | Tascenso Odt |
| Genentech USA, INC. | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Whitfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.